GlassScriptPhysician profile
Hema C Patel
NPI 1639186380
$8,083.76
in general payments reported to CMS, 2019-2025
54 companies · $1,139 in 2025
The $1,139 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,598 · 2020: $353 · 2021: $1,121 · 2022: $1,289 · 2023: $1,195 · 2024: $1,388 · 2025: $1,139.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,637 · Education: $85.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,637.21 |
| Education | $85.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,014.75 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $902.24 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $703.70 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $640.80 | 2019-2025 | Jardiance, Synjardy |
| Lilly USA, LLC | $494.60 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $409.37 | 2019-2024 | Xifaxan |
| Glaxosmithkline, LLC. | $338.38 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Pfizer INC. | $337.73 | 2019-2025 | |
| Amgen INC. | $315.27 | 2019-2025 | Repatha, Otezla, Repatha |
| Astellas Pharma US INC | $312.46 | 2019-2024 | Veozah, Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $283.55 | 2021-2025 | |
| Renalytix Ai, INC. | $187.69 | 2024-2025 | Kidneyintelx Blood Collection Convenience Kit |
| Sanofi-Aventis U.S. LLC | $151.04 | 2019-2025 | |
| Allergan, INC. | $142.77 | 2019-2020 | |
| Exact Sciences Corporation | $134.04 | 2023-2025 | Cologuard Collection Kit |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hema Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.